July newsletter

Cell Medica acquisition of WT1 T-cell therapy

Activity at CGT Catapult shows no sign of slowing down as we enter the summer period. We recently announced the acquisition of the WT1 t-cell therapy by Cell Medica, transferring intellectual property and commercialisation rights to the promising cancer immunotherapy. It was also announced that further development of the therapy will take place at the Cell and Gene Therapy Catapult manufacturing centre in Stevenage.